Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Combinations in First-Line ES-SCLC
NCT07245446Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, cadonilimab, ligufalimab in small cell lung cancer (SCLC), sponsored by Akeso, Inc.. Started Oct 2025; status: recruiting.
02
Drugs
ivonescimabcadonilimabligufalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07245446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07245446.